Intellia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics using CRISPR gene editing, oligonucleotides, and lipid nanoparticles. The company's lead product candidates are lonvoguran ziclumeran (lonvo-z) for hereditary angioedema and nexiguran ziclumeran (nex-z) for transthyretin amyloidosis, both of which are in Phase 3 clinical development as in vivo genome editing therapies. Intellia utilizes proprietary technologies to create single-dose, intravenous treatments designed to address the root causes of severe diseases. The company maintains a collaboration with Regeneron Pharmaceuticals to advance additional product candidates and is building a U.S.-focused commercial infrastructure to support the planned launch of its lead assets. Its research efforts focus on liver targets and expanding delivery technologies for diseases outside the liver.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage intelliatx.com
Sector Healthcare IR page ir.intelliatx.com
Tags
crispr gene editing, in vivo gene editing, rare diseases, hereditary angioedema, transthyretin amyloidosis, lipid nanoparticles, oligonucleotides, clinical stage, lonvoguran ziclumeran, lonvo-z, NTLA-2002, nexiguran ziclumeran, nex-z, NTLA-2001, HAELO, Regeneron Pharmaceuticals
Press page —

Metrics

Valuation  
Market cap $ 1.682B
Market cap (USD) $ 1.682B
P/E -3.60
PEG —
P/BV 2.74
P/S 31.80
P/OCF -4.73
P/FCF -4.70
Dividend yield —
Turnover / mcap —
Returns  
ROE -53.5%
ROI -70.8%
ROIC -56.8%
Profit margin -609.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 12.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 58
Quality score -38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 67.671M 57.877M 36.275M 52.121M 33.053M 57.994M 43.103M 30.434M — — —
Net profit -412.694M -519.021M -481.192M -474.186M -267.892M -134.231M -99.533M -85.343M -67.543M -31.634M -12.397M
Free cash flow -395.865M -354.658M -408.071M -346.845M -237.786M -53.497M -110.034M -67.615M -75.367M 29.944M -4.317M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 8.99 11.66 30.49 34.89 118.24 54.4 14.67 13.65 19.22 13.11 —
Price performance 12m -0.23 -0.62 -0.13 -0.7 1.17 2.71 0.07 -0.29 0.47 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 6.45M 10.5M 7.55M 4.62M 2.13M 2.03M 3.77M 36.5M 8.52M 9.47M
↳ YoY growth +545.4% +62.2% -27.9% -38.8% -53.9% -4.6% +85.5% +867.5% -76.6% +11.2%
↳ 5y CAGR +16.3% -20.6% -18.5% +37.0% +13.0% +34.8%
Borrowings, non-current (USD) — — — — — — — — — 0.00
Lease liabilities (USD) — — — 18.4M 39.3M 74M 131M 115M 210M 93.3M
Cash and deposits (USD) 273M 341M 58.9M 57.2M 160M 123M 524M 227M 189M 155M
Right-of-use assets (USD) — — — 19.1M 39.1M 79.1M 133M 115M 219M 106M
Net debt (borrowings + leases - cash) (USD) — — — — — — — — — -62.1M
Cash flow detail
Operating cash flow (USD) 36.1M -65.3M -61.3M -103M -49.9M -225M -333M -394M -349M -395M
Purchases of property, plant and equipment (USD) -6.17M -10.1M -6.36M -6.79M -3.59M -12.8M -13.6M -14M -5.78M -1.13M
Change in receivables (cash effect) (USD) -5.45M -4.02M 2.92M 2.93M 2.49M 99,000 -1.74M -32.7M 27.9M -951,000
Change in payables (cash effect) (USD) 1.78M -488,000 232,000 1.88M 5.06M 529,000 -4.58M 2.52M 6.8M 5.99M
Share-based compensation (USD) 6.72M 15.3M 17M 15.1M 19.9M 47M 91.4M 134M 154M 80.2M
Operating cash flow before change in receivables (USD) 41.6M -61.3M -64.2M -106M -52.4M -225M -332M -361M -377M -394M
Free cash flow (OCF - PPE - intangibles) (USD) 29.9M -75.4M -67.6M -110M -53.5M -238M -347M -408M -355M -396M
Income detail
Research and development expense (USD) 31.8M 67.6M 89.1M 108M 150M 230M 420M 435M 466M 389M
↳ 5y CAGR +68.2% +48.5% +44.1% +37.3% +33.9% +20.9%
Total comprehensive income (USD) -31.6M -67.5M -85.4M -99.2M -134M -271M -479M -476M -518M -412M
Comprehensive income to owners (USD) -31.6M -67.5M -85.4M -99.2M -134M -271M -479M -476M -518M -412M
Reported Feb 27, 2019 Feb 27, 2019 Feb 27, 2019 Feb 27, 2020 Feb 26, 2021 Feb 24, 2022 Feb 23, 2023 Feb 22, 2024 Feb 27, 2025 Nov 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 12, 2026, Intellia Therapeutics, Inc. (the “Company”) hosted a webcast for investors, analysts and others titled “Readying Lonvo-z for Patients with HAE.” A copy of the presentation presented at this event is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On November 12, 2026, Intellia Therapeutics, Inc. (the “Company”) hosted a webcast for investors, analysts and others titled “Readying Lonvo-z for Patients with HAE.” A copy of the presentation presented at this event is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

November 6, 2026

PDF Version

CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 12,900 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. [email protected]

Media Contact: Mike Tattory Vice President LifeSci Communications [email protected]

Primary Logo

Quick Links

RSS FEEDS

EMAIL ALERTS

PRINT PAGE

Prompts

Intellia Therapeutics, Inc. (ticker NTLA), listed in United States.

ETFs Holding Intellia Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 1.88% 3,497,291 $ 34.204M Nov 18, 2026
MEDX 1.12% 12,584 $ 212.921K Jun 30, 2026
ARKK 1.08% 14,063,687 $ 137.543M Nov 18, 2026
FSCC 0.33% 94,271 $ 1.2M Aug 31, 2026
HRTS 0.31% 13,708 $ 174.503K Aug 31, 2026
SEIS 0.26% 90,853 $ 1.537M Jun 30, 2026
FSEV 0.17% 670 $ 11.336K Jun 30, 2026
FESM 0.10% 344,292 $ 5.825M Jun 30, 2026
RESM 0.07% 156 $ 2,639.52 Jun 30, 2026
AVSC 0.07% 230,284 $ 2.271M Nov 16, 2026
DFAS 0.03% 794,660 $ 8.384M Nov 12, 2026
DXUV 0.01% 77,572 $ 818.385K Nov 12, 2026
MSSM 0.01% 7,110 $ 90.51K Aug 31, 2026
AVIE 0.01% 100 $ 986.00 Nov 16, 2026
DFAC 0.01% 580,026 $ 6.119M Nov 12, 2026
DCOR 0.00% 154,308 $ 1.628M Nov 12, 2026
DFAU 0.00% 36,517 $ 385.254K Nov 12, 2026
DFSU 0.00% 6,589 $ 69.514K Nov 12, 2026
DFUS 0.00% 46,919 $ 494.995K Nov 12, 2026
VFMO 0.00% 73 $ 929.29 Aug 31, 2026
AVUS 0.00% 13,957 $ 137.616K Nov 16, 2026